Research

A new biological treatment could replace chemotherapy in patients with aggressive breast cancer

Today the results of the phase 2 CORALLEEN clinical trial, promoted by the international academic group SOLTI, have been presented. The study, published in The Lancet Oncology, demonstrates that neoadjuvant treatment with ribociclib and letrozole is highly effective in patients with early hormone-sensitive breast cancer at high risk of developing distant metastases in the next 10 years.